


and compared  $^{18}\text{F}$ -fluciclovine PET/CT with multiparametric MR imaging, which is the standard usually employed by surgeons and oncologists to assess local extension of prostate cancer at original diagnosis. The authors found that  $^{18}\text{F}$ -fluciclovine PET had a higher sensitivity (68.8% vs 37.5%) but a lower specificity (57.9% vs. 87.5%) than multiparametric MR imaging for seminal vesicle infiltration; these results held true for evaluation of extracapsular extension (48.3% vs 44.3% and 83.3% vs 100%, respectively) (Fig. 12). They concluded that there does not appear to be a significant difference between the ability of  $^{18}\text{F}$ -fluciclovine PET/CT and multiparametric MR imaging in local staging of prostate cancer in newly diagnosed patients with high-risk prostate cancer. This was a challenging study to perform and provides important information that allows us to more appropriately reconcile the relative roles of imaging approaches in locally advanced prostate cancer at initial diagnosis.



**FIGURE 12.**  $^{18}\text{F}$ -fluciclovine PET/CT versus multiparametric MR imaging assessment of seminal vesicle invasion and extracapsular extension in primary prostate cancer. Example image in a 65-year-old man with primary prostate cancer (PSA = 47.92 ng/mL, Gleason score = 4.3).  $^{18}\text{F}$ -fluciclovine PET/CT (A) showed abnormal uptake in right seminal vesicle suggestive of invasion (blue arrow), whereas MR imaging (B) reported no evidence of seminal vesicle invasion. Histology confirmed right seminal vesicle invasion.

## SNMMI Bylaws Committee Notice to the Membership

**T**he SNMMI Bylaws Committee met in virtual video session on October 13, 2020, and approved several proposed amendments to the bylaws. In accordance with requirements for amending the bylaws, the proposed amendments are published herein. The amendments will be voted on by the House of Delegates during its virtual meeting, which will coincide with the SNMMI Mid-Winter Meeting in January 2021.

The amendments fall into 2 groups. The first would modify the election of Directors-at-Large to the Board of Directors. The SNMMI Task Force on Diversity, Equity, and Inclusion has recommended that a pathway be developed that would allow candidates for Director-at-Large positions to be selected from among qualified members in the general membership. This option would provide a pathway for members of underrepresented groups (as defined by the Association of American Medical Colleges) to enter SNMMI leadership

without being members of the House of Delegates. (Voting members of the House comprise delegates from Chapters, Councils, Centers, and the Technologist Section, as well as the SNMMI Historian.) At present the House of Delegates elects 4 Directors-at-Large from among its membership (excluding Technologist delegates). The proposed amendments provide for election of 2 Directors from among the full members of the Society and 2 Directors from among members of the House. The election of 3 Directors-at-Large by the Technologist Section is not changed by these amendments.

The second group of amendments includes housekeeping items that correct minor inconsistencies or errors and provide more consistent wording.

*Submitted on behalf of the Bylaws Committee by:*  
James M. Woolfenden, MD  
Chair

### Proposed Amendments to the SNMMI Bylaws

#### ARTICLE III MEMBERSHIP; Section 3: DISCIPLINE

- B. The Committee on Ethics shall review, either on its own initiative or on written and signed complaint, any case in which the circumstances in Sections 3:A or 4:A may lead to potential discipline and shall forward to the House of Delegates any recommendation on possible action. Such review shall afford the accused member an opportunity for a hearing.

#### ARTICLE VII HOUSE OF DELEGATES; Section 2: RESPONSIBILITIES

- A. To develop and recommend to the Board of Directors, Society policies and programs regarding professional issues affecting nuclear medicine and molecular imaging.  
B. To elect ~~the seven (7)~~ two (2) Directors-at-Large, ~~the majority of the voting members of the Board of Directors.~~  
C. To approve amendments to the Bylaws in accordance with the Bylaws and Procedures.

*(Continued on page 40N)*

- D. To approve establishment, suspension, renewal and dissolution of chapters and councils.
- E. To review the strategic plan annually.
- F. To oversee and monitor the work of the committees of the House of Delegates.
- G. To elect the Vice-Speaker of the House (who ascends to speaker), and the Historian.
- H. To elect the members-at-large of the Committee on Nominations.
- I. To elect the members of the Audit Committee.
- J. To approve the selection of the Editor of *The Journal of Nuclear Medicine*.

## ARTICLE VIII ELECTIONS; Section 2: COMMITTEE ON NOMINATIONS

- A. The Committee on Nominations shall consist of a Chair plus six additional members. The House of Delegates at the Annual Meeting shall elect the members of the committee, except the Chair, from among those who will continue to serve as voting members in the House the following year.
- B. The Committee on Nominations shall be chaired by the Past President—once-removed, who shall vote only in the case of a tie vote on the committee. If the Past President—once-removed is not able to serve, the next more senior available Past President shall chair the committee.
- C. The term of the Committee on Nominations shall commence at the conclusion of the Annual Meeting at which it is elected and shall terminate at the conclusion of the next Annual Meeting.
- D. The Committee on Nominations will solicit, verify, and submit to the membership ~~a slate of~~ candidates for Society Officers and two (2) Directors-at-Large.
- E. The Committee on Nominations shall solicit, verify, and submit to the House of Delegates ~~a slate of~~ candidates for Vice-Speaker of the House, Historian, and two (2) Directors-at-Large (other than Directors-at-Large chosen by the Technologist Section).

## ARTICLE X BOARD OF DIRECTORS; Section 3: COMPOSITION

The Board of Directors shall be composed of fifteen (15) voting members and six (6) non-voting members.

### A. Voting Members

- 1. Society Officers: President, Vice President, Vice President-Elect, and the Secretary/Treasurer. The President shall serve as Chair of the Board of Directors.
- 2. Immediate Past President
- 3. President of the Technologist Section
- 4. Immediate Past President of the Technologist Section
- 5. Speaker of the House of Delegates
- 6. Seven (7) Directors-at-Large
  - a) Directors-at-Large shall serve for a three (3)-year term, which shall commence at the conclusion of the Annual Meeting at which they are elected and which shall terminate at the conclusion of the third subsequent Annual Meeting following the election. A Director-at-Large chosen by the Technologist Section may serve for a term of less than three years at the discretion of the Technologist Section. Directors-at-Large may serve no more than two (2) consecutive terms, following which at least three years must elapse before service as a Director-at-Large is again permitted.
  - b) Candidates for Director-at-Large must have been a member of the Society for at least three (3) years to be eligible to serve on the Board of Directors.
  - c) ~~Four (4)~~ Two (2) Directors-at-Large shall be elected by the House of Delegates from among the voting Delegates of the House.
  - d) Two (2) Directors-at-Large shall be elected from among the Full members who are not House members or Technologist Section members.
  - e) Three (3) Directors-at-Large shall be elected by the Technologist Section from among the eight (8) Technologist Section Delegates of the House in accordance with procedures established by the Technologist Section.